Acquisition

B-cells in multiple myeloma
#Acquisition #Bispecific Antibodies #Dren Bio #Finance #Immunology #Sanofi

Bi-specific antibody acquisition broadens immunology pipeline

Sanofi and Dren Bio, a clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell engager (MCE) that has shown robust B-cell depletion in pre-clinical and early clinical studies. DR-0201 is a potential first-in-class CD20-directed bispecific antibody that… Read More

#Business & Investment #News

Human brain
#Acquisition #CNS #Excessive Daytime Sleepiness (EDS) #Narcolepsy #Neuraxpharm #Neuroscience #TG Therapeutics

Narcolepsy acquisitions to boost Neuraxpharm’s CNS reach

Pharmaceutical company Neuraxpharm, focused on the treatment of central nervous system (CNS) disorders, has acquired Provigil (modafinil) and Nuvigil (armodafinil), both of which are indicated for the treatment of Excessive Daytime Sleepiness (EDS) in adults with narcolepsy. Neuraxpharm has acquired these products in most markets outside the US, excluding the… Read More

#Business & Investment #News

#Acquisition #CatSci #Chromatography #Mergers and acquisitions

CatSci acquires chromatography provider Reach Separations

CatSci has acquired Reach Separations, a specialist chromatography provider for the analysis and purification of therapeutics. The acquisition was supported by Keensight Capital, private equity managers dedicated to pan-European Growth Buyout investments. Headquartered in the UK, and with laboratories in both the UK and… Read More

#Business & Investment #News

business deal
#Acquisition #Biotech #Drug development #Investment #Mergers and acquisitions

Novo Holdings acquires Catalent for $16.5 billion 

Catalent and Novo Holdings, a holding and investment company that manages the assets and wealth of the Novo Nordisk Foundation, have entered into a merger agreement under which Novo Holdings will acquire Catalent in an all-cash transaction that values Catalent at $16.5 billion.  Novo Holdings will acquire… Read More

#News

#Acquisition #Biopharma #Biotechnology #CDMO #Cell and gene therapy #Cold chain #Drug development #GSK #Pfizer #Regulatory #Supply chain

New podcast: A business case for drug discovery

This is the latest episode of the free DDW narrated podcast, “A business case for drug discovery”, which covers three articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “A deal in the making”, “Why project management… Read More

#News

handshake
#Acquisition #PARP inhibitors #Radiopharmaceuticals #Tumours

Ariceum Therapeutics expands pipeline with acquisition 

Ariceum Therapeutics, a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, has acquired Theragnostics, a UK-based private biopharmaceutical company engaged in the development of radio-labelled PARP inhibitors for the diagnosis and treatment of tumours.  The acquisition provides Ariceum with an… Read More

#News

Induced Pluripotent Stem Cells (iPSCs)
#Acquisition #allogeneic cell therapies #Cancer research #Eterna Therapeutics #Exacis Biotherapeutics #Immuno-oncology #iPSC

Eterna acquires Exacis’ allogeneic immuno-oncology platform

Eterna Therapeutics, a life science company focused on mRNA cell engineering, has acquired Exacis Biotherapeutics’ immuno-oncology platform. The acquisition will provide Eterna with a pipeline of allogeneic immuno-oncology products under development for the treatment of haematologic and solid tumours. The deal also provides Eterna… Read More

#Business & Investment #News

Remyelination
#Acquisition #CNS #Drug discovery #Pheno Therapeutics #Phenomics #Phenotyping

Pheno Therapeutics buys rights to potential remyelination drug

Pheno Therapeutics has entered an agreement with UCB for the rights to develop, manufacture and commercialise a preclinical-stage programme of novel small molecules designed to promote remyelination.   “Pheno Therapeutics utilised its proprietary human phenotypic screening platform to discover novel and tractable therapeutic targets to modulate oligodendrocyte biology… Read More

#Business & Investment #News

Patient checking own blood pressure
#Acquisition #AstraZeneca #Chronic kidney disease (CKD) #Hypertension #Mergers and acquisitions

AstraZeneca gains rights to novel aldosterone synthase inhibitor

AstraZeneca has entered into an agreement to acquire CinCor Pharma, a clinical-stage biopharmaceutical company, focused on developing treatments for resistant and uncontrolled hypertension as well as chronic kidney disease.  As part of the deal, the company will acquire CinCor’s candidate drug, baxdrostat (CIN-107), an aldosterone synthase inhibitor… Read More

#Business & Investment #Editor's Choice #News

#Acquisition #AmerisourceBergen #Drug discovery #Mergers and acquisitions #Pharma services #PharmaLex

AmerisourceBergen completes acquisition of PharmaLex

AmerisourceBergen Corporation has completed its acquisition of PharmaLex Holding, a provider of tech-enabled services from clinical development consulting to marketing authorisation.  PharmaLex is a global team of scientific, regulatory and safety and compliance (GxP) experts that provide strategic guidance and regulatory support to biopharma companies throughout a… Read More

#Business & Investment #News

#Acquisition #Clinical trials #Life sciences

Beckley Psytech acquires Eleusis Therapeutics

Clinical stage company Beckley Psytech has entered into an agreement to acquire clinical-stage life science company, Eleusis Therapeutics.   Under the terms of the agreement, which has been approved by shareholders, Beckley Psytech has acquired 100% of Eleusis, receiving full developmental and commercial rights for the company’s assets… Read More

#News

#Acquisition #Biorepository #Biospecimen collection #Mergers and acquisitions

BioIVT expands into new therapy areas with Fidelis acquisition

BioIVT has acquired Fidelis Research, an 85-site clinical biospecimen collection network in Southeastern Europe.  Fidelis Research also possesses cell isolation capabilities and provides custom contract research services for pharmaceutical companies and clinical research organisations (CROs).  “This transaction increases BioIVT’s global operations by adding new clinical collection sites, which… Read More

#News

#Acquisition #GSK #Oncology

GSK completes acquisition of Sierra Oncology  

GSK has completed its acquisition of the biopharmaceutical company Sierra Oncology, boosting its portfolio of oncology medicines.  The deal was announced back in April this year and sees GSK acquiring Sierra Oncology for a total of $1.9 billion. The acquisition will give GSK access to Sierra’s late-stage… Read More

#Business & Investment #News

#Acquisition #GSK #Pfizer

A deal in the making

Listen to this article on the DDW Podcast: Drug Discovery World Editor Reece Armstrong looks at how a number of deals in pharma have sparked excitement in the industry.  A number of recently announced deals by pharma companies has brought some excitement back into the sector after a… Read More

#Business & Investment #Exclusive Content

#Acquisition #Biohaven #Migraine #Pfizer

Pfizer to buy Biohaven for $11.6bn

Pfizer is to acquire commercial-stage biopharmaceutical company Biohaven in a deal worth $11.6 billion. Biohaven is developing therapies for the treatment of migraine. The company’s lead product NURTEC ODT is a dual-acting migraine therapy which has been approved in the US for adult patients. The therapy has also been approved… Read More

#Business & Investment #News